JP2024534468A5 - - Google Patents
Info
- Publication number
- JP2024534468A5 JP2024534468A5 JP2024517044A JP2024517044A JP2024534468A5 JP 2024534468 A5 JP2024534468 A5 JP 2024534468A5 JP 2024517044 A JP2024517044 A JP 2024517044A JP 2024517044 A JP2024517044 A JP 2024517044A JP 2024534468 A5 JP2024534468 A5 JP 2024534468A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- hil
- acid sequence
- polypeptide
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245523P | 2021-09-17 | 2021-09-17 | |
| US63/245,523 | 2021-09-17 | ||
| PCT/US2022/043762 WO2023043978A2 (en) | 2021-09-17 | 2022-09-16 | Caix targeting il-12 fusion proteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534468A JP2024534468A (ja) | 2024-09-20 |
| JP2024534468A5 true JP2024534468A5 (cg-RX-API-DMAC7.html) | 2025-09-04 |
Family
ID=85603506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517044A Pending JP2024534468A (ja) | 2021-09-17 | 2022-09-16 | Caix標的化il-12融合タンパク質およびそれらの使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240392031A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4402158A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534468A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240161081A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118369331A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022345103A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232632A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL311442A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003275A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023043978A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202402034B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200089312A (ko) | 2017-11-28 | 2020-07-24 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| EP3981428A4 (en) | 2019-06-05 | 2023-07-12 | Chugai Seiyaku Kabushiki Kaisha | Protease substrate, and polypeptide including protease cleavage sequence |
| CN115943210A (zh) | 2020-01-20 | 2023-04-07 | 中外制药株式会社 | 配体结合融合蛋白 |
| CN120035602A (zh) * | 2022-06-17 | 2025-05-23 | 辉瑞公司 | Il-12变体、抗-pd1抗体、融合蛋白及其用途 |
| EP4739701A2 (en) * | 2023-07-07 | 2026-05-13 | Technische Universität München, in Vertretung des Freistaats Bayern | Muteins of human interleukin 12 |
| WO2025101133A1 (en) * | 2023-11-10 | 2025-05-15 | Agency For Science, Technology And Research | Interleukin-12 variants and medical uses thereof |
| AU2024407051A1 (en) | 2023-12-18 | 2026-07-30 | Genzyme Corporation | Il-12 loss of potency muteins |
| WO2025205534A1 (ja) * | 2024-03-25 | 2025-10-02 | 積水メディカル株式会社 | 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1418184A1 (en) * | 2002-11-08 | 2004-05-12 | Cell Center Cologne GmbH | Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof |
| SI1966238T1 (sl) * | 2005-12-30 | 2012-08-31 | Merck Patent Gmbh | Variante interlevkina-12P40 z izboljšano stabilnostjo |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| KR102884523B1 (ko) * | 2018-10-03 | 2025-11-10 | 젠코어 인코포레이티드 | IL-12 이종이량체 Fc-융합 단백질 |
| EP4037700A2 (en) * | 2019-10-03 | 2022-08-10 | Xencor, Inc. | Targeted il-12 heterodimeric fc-fusion proteins |
| JP7851612B2 (ja) * | 2020-04-17 | 2026-04-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 改変il-12及びil-23ポリペプチドとその使用 |
-
2022
- 2022-09-16 CA CA3232632A patent/CA3232632A1/en active Pending
- 2022-09-16 IL IL311442A patent/IL311442A/en unknown
- 2022-09-16 CN CN202280076070.8A patent/CN118369331A/zh active Pending
- 2022-09-16 AU AU2022345103A patent/AU2022345103A1/en active Pending
- 2022-09-16 EP EP22870726.1A patent/EP4402158A4/en active Pending
- 2022-09-16 WO PCT/US2022/043762 patent/WO2023043978A2/en not_active Ceased
- 2022-09-16 MX MX2024003275A patent/MX2024003275A/es unknown
- 2022-09-16 JP JP2024517044A patent/JP2024534468A/ja active Pending
- 2022-09-16 KR KR1020247012576A patent/KR20240161081A/ko active Pending
-
2024
- 2024-03-12 ZA ZA2024/02034A patent/ZA202402034B/en unknown
- 2024-03-15 US US18/607,049 patent/US20240392031A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2801873T3 (es) | Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos | |
| JP6359372B2 (ja) | DARPinを含む二重特異キメラ蛋白質 | |
| CN113260379B (zh) | 蛋白酶可切割的双特异性抗体及其用途 | |
| ES2432792T5 (es) | Dominio de unión a CD3-épsilon específico de especies cruzadas | |
| JP2022516557A5 (cg-RX-API-DMAC7.html) | ||
| CA3199566A1 (en) | Anti-cd276 antibody, antibody-drug conjugate, and use thereof | |
| WO2006020258A2 (en) | Novel tetravalent bispecific antibody | |
| CN101432015A (zh) | 功能性抗体 | |
| EP2784091B1 (en) | Bispecific anti-cMet/anti-Her2 antibodies | |
| KR20230053602A (ko) | 항-ror1 항체 및 관련된 이중특이적 결합 단백질 | |
| WO2023174396A1 (zh) | 一种新型免疫调节剂的开发和应用 | |
| Müller et al. | Bispecific Antibodies | |
| JP2024504124A5 (cg-RX-API-DMAC7.html) | ||
| JP7738914B2 (ja) | TriAx抗体の組成、その製造方法及び使用方法 | |
| JP2024521701A (ja) | 抗cd137抗体及びその使用方法 | |
| JP2025504795A5 (cg-RX-API-DMAC7.html) | ||
| WO2024153168A2 (en) | Anti-cmet antibodies and methods of use | |
| JP2026514663A (ja) | Tnfスーパーファミリーメンバー免疫サイトカイン及びその使用 | |
| CN120271715A (zh) | 抗体及其药物偶联物和用途 | |
| EP4483899A1 (en) | Medicine comprising combination of anti-mutant-calr antibody and another drug | |
| WO2025140489A1 (en) | Multispecific antibodies and uses thereof | |
| WO2025045018A1 (en) | Anti-gamma delta tcr antibodies and uses thereof | |
| WO2026057723A1 (en) | Claudin-1/egfr bispecific antibodies for targeted degradation | |
| WO2025255480A1 (en) | Tetravalent multispecific binding molecules and methods of use thereof | |
| WO2024032617A1 (zh) | 异多聚体蛋白质及其制备方法 |